Literature DB >> 21510827

Opportunities and challenges for the development of antisense treatment in neuromuscular disorders.

Maaike van Putten1, Annemieke Aartsma-Rus.   

Abstract

INTRODUCTION: Neuromuscular disorders are diseases of the musculature and/or the nervous system, generally leading to loss of muscle function. They are a frequent cause of disability and treatment options are often only symptomatic. Interestingly, for a number of neuromuscular disorders the application of antisense oligonucleotides has therapeutic potential. AREAS COVERED: The authors describe how this approach is exploited for different neuromuscular diseases, focusing on literature published in the past 10 years. For each disease the opportunities of this approach, the state of the art, and current challenges are described. EXPERT OPINION: A lot of progress has been made in the development of antisense-mediated approaches during recent years and they may become clinically applicable in the near future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21510827     DOI: 10.1517/14712598.2011.579098

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  2 in total

1.  Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy.

Authors:  Ingrid E C Verhaart; Hans Heemskerk; Tatyana G Karnaoukh; Ingrid G M Kolfschoten; Anne Vroon; Gert-Jan B van Ommen; Judith C T van Deutekom; Annemieke Aartsma-Rus
Journal:  Hum Gene Ther       Date:  2012-01-26       Impact factor: 5.695

Review 2.  Cytokines and chemokines as regulators of skeletal muscle inflammation: presenting the case of Duchenne muscular dystrophy.

Authors:  Boel De Paepe; Jan L De Bleecker
Journal:  Mediators Inflamm       Date:  2013-11-05       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.